Related Experiment Video
Updated: Feb 8, 2026

DNAzyme-dependent Analysis of rRNA 2’-O-Methylation
Published on: September 16, 2019
Anti-replicative recombinant 5S rRNA molecules can modulate the mtDNA heteroplasmy in a glucose-dependent manner
Romuald Loutre1, Anne-Marie Heckel1, Damien Jeandard1
1UMR 7156 Génétique Moléculaire, Génomique, Microbiologie (GMGM), Strasbourg University-CNRS, Strasbourg, France.
Abstract:
Mutations in mitochondrial DNA are an important source of severe and incurable human diseases. The vast majority of these mutations are heteroplasmic, meaning that mutant and wild-type genomes are present simultaneously in the same cell. Only a very high proportion of mutant mitochondrial DNA (heteroplasmy level) leads to pathological consequences. We previously demonstrated that mitochondrial targeting of small RNAs designed to anneal with mutant mtDNA can decrease the heteroplasmy level by specific inhibition of mutant mtDNA replication, thus representing a potential therapy. We have also shown that 5S ribosomal RNA, partially imported into human mitochondria, can be used as a vector to deliver anti-replicative oligoribonucleotides into human mitochondria. So far, the efficiency of cellular expression of recombinant 5S rRNA molecules bearing therapeutic insertions remained very low. In the present study, we designed new versions of anti-replicative recombinant 5S rRNA targeting a large deletion in mitochondrial DNA which causes the KSS syndrome, analyzed their specific annealing to KSS mitochondrial DNA and demonstrated their import into mitochondria of cultured human cells. To obtain an increased level of the recombinant 5S rRNA stable expression, we created transmitochondrial cybrid cell line bearing a site for Flp-recombinase and used this system for the recombinase-mediated integration of genes coding for the anti-replicative recombinant 5S rRNAs into nuclear genome. We demonstrated that stable expression of anti-replicative 5S rRNA versions in human transmitochondrial cybrid cells can induce a shift in heteroplasmy level of KSS mutation in mtDNA. This shift was directly dependent on the level of the recombinant 5S rRNA expression and the sequence of the anti-replicative insertion. Quantification of mtDNA copy number in transfected cells revealed the absence of a non-specific effect on wild type mtDNA replication, indicating that the decreased proportion between mutant and wild type mtDNA molecules is not a consequence of a random repopulation of depleted pool of mtDNA genomes. The heteroplasmy change could be also modulated by cell growth conditions, namely increased by cells culturing in a carbohydrate-free medium, thus forcing them to use oxidative phosphorylation and providing a selective advantage for cells with improved respiration capacities. We discuss the advantages and limitations of this approach and propose further development of the anti-replicative strategy based on the RNA import into human mitochondria.
Insights
Mitochondrial DNA (mtDNA) mutations cause incurable diseases. This study developed a novel therapy using engineered 5S ribosomal RNA to reduce mutant mtDNA levels in KSS syndrome cells, showing promise for treating mitochondrial disorders.
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- Mitochondrial DNA (mtDNA) mutations are linked to severe human diseases, often presenting as heteroplasmy.
- Current therapeutic strategies face challenges in efficiently targeting mutant mtDNA replication.
Purpose of the Study:
- To develop and evaluate a novel therapeutic approach using recombinant 5S ribosomal RNA (rRNA) to reduce heteroplasmy levels in Kearns-Sayre syndrome (KSS) by targeting mtDNA deletions.
- To enhance the stable expression of therapeutic rRNA molecules within human cells for potential in vivo application.
Main Methods:
- Designed and synthesized anti-replicative recombinant 5S rRNA targeting KSS mtDNA deletions.
- Validated specific annealing and mitochondrial import of engineered rRNA in cultured human cells.
- Established a transmitochondrial cybrid cell line for recombinase-mediated integration of therapeutic rRNA genes into the nuclear genome.
- Assessed heteroplasmy shifts and mtDNA copy numbers under varying cellular conditions.
Main Results:
- Engineered 5S rRNA molecules specifically annealed to KSS mtDNA and were imported into mitochondria.
- Stable expression of recombinant 5S rRNA in cybrid cells induced a shift in KSS heteroplasmy levels.
- The observed heteroplasmy shift was dependent on recombinant rRNA expression levels and insertion sequence, without affecting wild-type mtDNA replication.
- Cellular growth conditions, such as carbohydrate-free media, modulated heteroplasmy changes, favoring cells with improved oxidative phosphorylation.
Conclusions:
- Stable expression of anti-replicative 5S rRNA is a viable strategy to reduce mutant mtDNA heteroplasmy in KSS.
- The approach demonstrates specificity and avoids off-target effects on wild-type mtDNA.
- Further development of RNA-based mitochondrial therapies holds significant potential for treating heteroplasmic mtDNA diseases.
More Related Videos
15:57Visualizing Single-molecule DNA Replication with Fluorescence Microscopy
Published on: October 9, 2009
11:53Derivation of Highly Purified Cardiomyocytes from Human Induced Pluripotent Stem Cells Using Small Molecule-modulated Differentiation and Subsequent Glucose Starvation
Published on: March 18, 2015
Related Concept Videos
Replication in Prokaryotes
Recombinant DNA
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Homologous Recombination
Replication in Eukaryotes
Viral Recombination